New Research Suggests Amlodipine May Help Manage ADHD Symptoms
A widely used blood pressure medication, amlodipine, may offer a new treatment option for attention-deficit/hyperactivity disorder (ADHD), according to an international study involving the University of Surrey. Published in Neuropsychopharmacology, the study provides compelling evidence from animal models, genetic analysis, and patient data that supports the drug’s potential for managing ADHD symptoms.
Key Findings from the Study
Researchers initially tested five potential drugs in rats with ADHD-like symptoms, finding that only amlodipine effectively reduced hyperactivity. To validate these results, they conducted further experiments on zebrafish, a species that shares about 70% of its genes with humans and is commonly used in brain research. The zebrafish study confirmed that amlodipine reduced hyperactivity and impulsivity—two key symptoms of ADHD—and, for the first time, demonstrated that the drug can cross the blood-brain barrier, allowing it to directly affect brain function.
Further genetic analysis revealed that ADHD is linked to calcium channels in the brain—the same pathways targeted by amlodipine. This discovery strengthens the case for using calcium channel blockers in ADHD treatment. Additionally, a review of medical records from across the UK indicated that individuals taking amlodipine experienced fewer mood swings and engaged in less risk-taking behavior, further supporting its potential benefits for ADHD patients.
A Safer Alternative to Traditional ADHD Medications?
Existing ADHD treatments, though effective, often come with significant side effects such as appetite suppression, high blood pressure, headaches, and sleep disturbances. Some medications also carry a risk of misuse. Since amlodipine is already widely prescribed, well-tolerated, and approved for use, researchers suggest that repurposing it for ADHD could provide a safer and faster alternative to current treatment options.
Dr. Matthew Parker, co-author of the study from the University of Surrey, highlighted the potential impact of this research:
“Repurposing amlodipine, a well-established blood pressure medication, offers a promising and swift pathway to address ADHD symptoms. Our research indicates that, due to its existing approval and safety profile, amlodipine could be rapidly redeployed as a treatment option for ADHD, potentially providing relief to patients sooner than developing new medications.”
Addressing the Need for New ADHD Treatments
With approximately 25% of ADHD patients not responding well to current medications, there is an urgent need for alternative treatments. This study paves the way for further clinical trials to evaluate amlodipine’s effectiveness in ADHD patients.
As research continues, the possibility of repurposing existing medications for ADHD could open new doors for treatment options, offering hope for those who struggle with the disorder and experience limited success with current therapies.
Add comment